A liposomal steroid nano-drug for treating systemic lupus erythematosus

Lupus

Volumn 25, Issue 11, 2016, Pages 1209-1216

  Moallem, E ^a   Koren, E ^b   Ulmansky, R ^a   Pizov, G ^a   Barlev, M ^b   Barenholz, Y ^b   Naparstek, Y ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

corticosteroids; Systemic lupus erythematosus; treatment

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; ANTINUCLEAR ANTIBODY; LIPOSOME; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HISTOPATHOLOGY; KIDNEY INJURY; LIPOSOMAL DELIVERY; LYMPHOCYTE PROLIFERATION; LYMPHOID TISSUE; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; STEROID THERAPY; SURVIVAL; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY EFFECT; ANIMAL; DISEASE MODEL; DRUG ADMINISTRATION; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, ANTINUCLEAR; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; LIPOSOMES; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHYLPREDNISOLONE HEMISUCCINATE; MICE; MICE, INBRED MRL LPR; NANOPARTICLES; TREATMENT OUTCOME;

EID: 84987670053     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316636468     Document Type: Article

References (21)

1. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus. Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: Report of a consensus meeting. Arthritis Rheum 2004; 50: 3427-3431.
2. Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013; 72: 1905-1913.
3. Wofsy D,. Recent progress in conventional and biologic therapy for systemic lupus erythematosus. Ann Rheum Dis 2013; 72 (Suppl. 2): ii66-ii68.
4. Avnir Y, Turjeman K, Tulchinsky D, et al. Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids. PLoS One 2011; 10: e25721-e25721.
5. Avnir Y, Ulmansky R, Wasserman V, et al. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: A novel approach to treating autoimmune arthritis. Arthritis Rheum 2008; 58: 119-129.
6. Ozbakir B, Crielaard BJ, Metselaar JM, Storm G, Lammers T,. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. J Control Release 2014; 190: 624-636.
7. Quan L, Zhang Y, Crielaard BJ, et al. Nanomedicines for inflammatory arthritis: Head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano 2014; 8: 458-466.
8. Turjeman K, et al. Nano-drugs based on nano sterically stabilized liposomes for the treatment of inflammatory neurodegenerative diseases. PLoS One 2015; 10: e0130442-e0130442.
9. Ulmansky R, Turjeman K, Baru M, et al. Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J Control Release 2012; 160: 299-305.
10. Guo J, Waknine-Grinberg JH, Mitchell AJ, Barenholz Y, Golenser J,. Reduction of experimental cerebral malaria and its related proinflammatory responses by the novel liposome-based beta-methasone nanodrug. Biomed Res Int 2014; 2014: 292471-292471.
11. Waknine-Grinberg JH, Even-Chen S, Avichzer J, et al. Glucocorticosteroids in nano-sterically stabilized liposomes are efficacious for elimination of the acute symptoms of experimental cerebral malaria. PLoS One 2013; 8: e72722-e72722.
12. Heydemann A,. The super super-healing MRL mouse strain. Front Biol 2012; 7: 522-538.
13. Perry D, Sang A, Yin Y, Zheng YY, Morel L,. Murine models of systemic lupus erythematosus. J Biomed Biotechnol 2011; 2011: 271694-271694.
14. Anderson BD, Taphouse V,. Initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate. J Pharm Sci 1981; 70: 181-186.
15. Barenholz Y and Amselem S Quality control assays in the development and clinical use of liposome-based formulations. In: Gregoriadis G (ed.) Liposome Technology, 2nd Edn, Vol. I, Liposome Preparation and Related Techniques, Boca Raton, FL: CRC Press, 1993, pp. 527 - 616.
16. Bartlett GR,. Phosphorus assay in column chromatography. J Biol Chem 1959; 234: 466-468.
17. Luijten RK, Fritsch-Stork RD, Bijlsma JW, Derksen RH,. The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Rev 2013; 12: 617-628.
18. Rhen T, Cidlowski JA,. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1123-1711-1123.
19. Schacke H, Docke WD, Asadullah K,. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43.
20. Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 2004; 101: 227-232.
21. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731.